| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2023-02-19 |
| タイトル |
|
|
タイトル |
Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
angiogenesis inhibitor |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
curcumin analog |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
fibronectin |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
sorafenib |
| 主題 |
|
|
主題Scheme |
Other |
|
主題 |
sunitinib |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 作成者 |
Shimazu, Kazuhiro
Inoue, Masahiro
Sugiyama, Shunsuke
Fukuda, Koji
Yoshida, Taichi
Taguchi, Daiki
Uehara, Yoshihiko
Kuriyama, Sei
Tanaka, Masamitsu
Miura, Masatomo
Nanjyo, Hiroshi
Iwabuchi, Yoshiharu
Shibata, Hiroyuki
|
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Tumor angiogenesis inhibition is one of the most potent strategies in cancer chemotherapy. From past clinical studies, inhibition of the vascular endothelial growth factor pathway successfully treats malignant tumors. However, vascular endothelial growth factor inhibitors alone cannot cure tumors. Moreover, resistance to small molecule inhibitors has also been reported. Herein, we show the antiangiogenic potential of a newly synthesized curcumin analog, GO-Y078, that possibly functions through inhibition of actin stress fiber formation, resulting in mobility inhibition; this mechanism is different from that of vascular endothelial growth factor inhibition. In addition, we examined the detailed mechanism of action of the antiangiogenesis potential of GO-Y078 using human umbilical venous epithelial cells resistant to angiogenesis inhibitors (HUVEC-R). GO-Y078 inhibited the growth and mobility of HUVEC-R at 0.75mol/L concentration. Expression analyses by microarray and RT-PCR showed that expressions of genes including that of fibronectin 1 were significantly suppressed. Among these genes, fibronectin 1 is abundantly expressed and, therefore, seems to be a good target for GO-Y078. In a knockdown experiment using Si-oligo of fibronectin 1 (FN1), FN1 expression was decreased to half of that in mock experiments as well as GO-Y078. Knockdown of FN1 resulted in the suppression of HUVEC-R growth at 24hours after treatment. Fibronectin is a key molecule contributing to angiogenesis that could be inhibited by GO-Y078. Thus, resistance to vascular endothelial growth factor inhibition can be overcome using GO-Y078. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 書誌情報 |
en : Cancer Science
巻 109,
号 10,
p. 3285-3293,
発行日 2018
|
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1349-7006 |
| 出版者 |
|
|
出版者 |
John Wiley and Sons Inc |
| 関連情報 |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/cas.13741 |
| 権利情報 |
|
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction inany medium, provided the original work is properly cited and is not used for commercial purposes.© 2018 The Authors.Cancer Sciencepublished by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
iA_2022_46.pdf (581.2 kB)
